Alnylam Pharmaceuticals, Inc. (ALNY): Total Liabilities
$4.18B
As of 2025-12-31
$4.20B
As of 2026-06-30
+4.1%
3-year compound annual growth
+11.8%
5-year compound annual growth
+42.4%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.18B | +0.1% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $4.17B | +3.0% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $4.05B | +9.3% | 2025-02-13, Balance as of period end |
| 2022-12-31 | $3.70B | +21.3% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $3.06B | +27.8% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $2.39B | +150.0% | 2022-02-10, Balance as of period end |
| 2019-12-31 | $956.44M | +250.6% | 2021-02-11, Balance as of period end |
| 2018-12-31 | $272.84M | +19.5% | 2020-02-13, Balance as of period end |
| 2017-12-31 | $228.30M | -33.4% | 2019-02-14, Balance as of period end |
| 2016-12-31 | $342.59M | +181.3% | 2018-02-15, Balance as of period end |
| 2015-12-31 | $121.80M | -15.0% | 2017-02-15, Balance as of period end |
| 2014-12-31 | $143.33M | -4.6% | 2016-02-12, Balance as of period end |
| 2013-12-31 | $150.18M | -2.1% | 2015-02-13, Balance as of period end |
| 2012-12-31 | $153.47M | -6.4% | 2014-02-20, Balance as of period end |
| 2011-12-31 | $163.92M | -30.3% | 2013-02-19, Balance as of period end |
| 2010-12-31 | $235.03M | -22.5% | 2012-02-13, Balance as of period end |
| 2009-12-31 | $303.42M | n/a | 2011-02-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $4.18B | +0.1% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $5.60B | +5.1% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $1.51B | +13.2% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $783.80M | -14.8% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $6.81B | +4.5% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $3.83B | +47.9% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $9.91B | +25.7% |
| Organon & Co. (OGN) | 2025-12-31 | $12.12B | -4.1% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $2.21B | -9.3% |
Compare ALNY, PRGO, BMRN, UTHR side by side · Screen every company in Pharmaceutical Preparations ↗